Skip to main content

ML Strategies

Viewpoints

Filter by:

Lobbying and Public Policy Viewpoints Thumbnail

Post-Election 2020 - Health Care Preview

November 23, 2020 | Blog | By Alexander Hecht, Anthony DeMaio, Aaron Josephson, Brett Else, Tara E. Dwyer, Ellyn Sternfield

With the presidential transition underway, we now look forward to what the Biden administration will seek to accomplish, particularly in the realm of health care policy.
Read more
Lobbying and Public Policy Viewpoints Thumbnail

Senate Passes IoT Cybersecurity Bill by Unanimous Consent

November 18, 2020 | Blog | By Christian Tamotsu Fjeld, Christopher Harvie

Read more
Lobbying and Public Policy Viewpoints Thumbnail

Massachusetts Congressional Delegation to the 117th Congress

November 10, 2020 | Blog | By Anthony DeMaio

Read about the Massachusetts congressional delegation to the 117th Congress, their current and potential committee assignments, and possible policy implications.
Read more
Lobbying and Public Policy Viewpoints Thumbnail

MLS Election Update: Impact on Trade

November 10, 2020 | Blog | By R. Neal Martin, Robert Kidwell, Alexander Hecht, Anthony DeMaio

Read about the post-election impact on international trade matters and the incoming administration's influence on the Committee on Foreign Investments in the U.S. (CFIUS).
Read more
Lobbying and Public Policy Viewpoints Thumbnail

MLS Election Update: Clean Tech, Energy & Environment

November 9, 2020 | Blog | By R. Neal Martin

Read about how the administration of President-Elect Joe Biden could shape clean tech, energy, and environmental policy in a divided government.
Read more
Lobbying and Public Policy Viewpoints Thumbnail

Twitter, Facebook, Google Heads Testify on Section 230 and Local Journalism

October 29, 2020 | Blog | By Christian Tamotsu Fjeld, Christopher Harvie

Read more
Health Care Viewpoints Thumbnail
You’d be forgiven in the current climate of coronavirus and election season, to name just a couple hot issues of the day, for missing two recent announcements from the FDA about its digital health program. On September 14, 2020, FDA published “Developing the Software Precertification Program: Summary of Learnings and Ongoing Activities” and the following week, on September 22, launched the Digital Health Center of Excellence.
Read more
Lobbying and Public Policy Viewpoints Thumbnail

Executive Compensation Practices in Pharma – Insight into Congressional Oversight

October 7, 2020 | Blog | By Alexander Hecht, Anthony DeMaio

Read more
Lobbying and Public Policy Viewpoints Thumbnail

Massachusetts Legislature Negotiating Extending the 2019-2020 Session Beyond July 31st

July 30, 2020 | Blog | By Steven Baddour, Daniel Connelly, Kaitlyn Sprague, Taylor Shepherd

Read more
Health Care Viewpoints Thumbnail

Beyond COVID: House Committee Advances Several FDA-Related Bills

July 23, 2020 | Blog | By Aaron Josephson, Margaret Jewett

Despite the COVID-19 pandemic, the House Energy & Commerce Committee continues work on several health policy issues, including Orphan Drug Act reform and continuous manufacturing.
Read more
Lobbying and Public Policy Viewpoints Thumbnail

Senate & House Advance PPP Extension: Setting Stage for Next COVID-19 Stimulus Package

July 2, 2020 | Blog | By Alexander Hecht, R. Neal Martin, Anthony DeMaio

Read more
Lobbying and Public Policy Viewpoints Thumbnail

The Implications of Trump's Executive Order and Section 230 of the Communications Decency Act

June 3, 2020 | Blog | By Christian Tamotsu Fjeld, Christopher Harvie

Read more

Massachusetts’ Speaker of the House Robert DeLeo Delivers Remote Chamber Address on Vision for the Remainder of Legislative Session

May 21, 2020 | Blog | By Steven Baddour, Daniel Connelly, Caitlin Beresin, Kaitlyn Sprague, Taylor Shepherd

Read more
Lobbying and Public Policy Viewpoints Thumbnail

Massachusetts’ Reopening Advisory Board Releases Reopening Report

May 18, 2020 | Blog | By Steven Baddour, Daniel Connelly, Kaitlyn Sprague, Caitlin Beresin, Taylor Shepherd

Today, the Baker-Polito Administration’s Reopening Advisory Board published their report outlining a 4-phase schedule for reopening the Commonwealth since the closure of non-essential businesses on March 23.
Read more
Lobbying and Public Policy Viewpoints Thumbnail
This update covers federal and Massachusetts responses to the pandemic, including the House Democrats’ phase 4 economic stimulus proposal, the SBA’s report on PPP implementation plus criticism of how it manages EIDL, and Massachusetts’s reopening plan and its proposed $1B supplemental budget to cover Covid-19 spending.
Read more
Health Care Viewpoints Thumbnail

Next Steps for 21st Century Cures 2.0

May 8, 2020 | Blog | By Aaron Josephson

On Monday, April 27, Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) announced the next steps for 21st Century Cures 2.0 (Cures 2.0), legislation that will build on the original 21st Century Cures Act enacted in December 2016 (Cures 1.0). While Cures 1.0 aimed to speed up the process of bringing new treatments to market, Cures 2.0 is generally envisioned to emphasize public health and streamlined care delivery, particularly in light of the COVID-19 pandemic. Elements envisioned to be in Cures 2.0 were outlined in a recently published concept paper that we discuss in this post.
Read more
Lobbying and Public Policy Viewpoints Thumbnail
This update covers federal and Massachusetts responses to the pandemic, including the U.S. Treasury Implementation of CARES Act programs, new proposals for small- and mid-sized businesses, the Paycheck Protection Program (PPP), and new Massachusetts rules related to masks, car dealers, and retailers.
Read more
Health Care Viewpoints Thumbnail

Rough Seas for COVID-19 Serology Tests Lead to Course Correction by FDA

May 5, 2020 | Blog | By Joanne Hawana, Hope Foster, Aaron Josephson

Responding to increased public and congressional criticism of its arguably too-flexible approach to regulatory oversight of serological tests used to detect COVID-19 antibodies, on May 4, 2020 the Food and Drug Administration (FDA) announced a revised policy aimed at reducing the risks associated with such tests.
Read more
Sign up to receive email updates from Mintz.
Subscribe Now

Explore Other Viewpoints: